Accounting for approximately 15–20% of all total breast cancer cases, triple negative breast cancer (TNBC) is one of most aggressive breast cancer subtypes, with poorer prognosis than ER/PR positive or Her2 overexpressed breast cancer due to a lack of targeted therapy [2,3,4]. The gene discussed is ERBB2; the disease is breast carcinoma.